Home » Stocks » ALLK

Allakos Inc. (ALLK)

Stock Price: $107.16 USD 1.81 (1.72%)
Updated Apr 22, 2021 4:00 PM EDT - Market closed
Market Cap 5.64B
Revenue (ttm) n/a
Net Income (ttm) -153.48M
Shares Out 49.49M
EPS (ttm) -3.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 22
Last Price $107.16
Previous Close $105.35
Change ($) 1.81
Change (%) 1.72%
Day's Open 107.30
Day's Range 105.39 - 110.18
Day's Volume 178,541
52-Week Range 55.51 - 157.98

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

REDWOOD CITY, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil...

3 days ago - GlobeNewsWire

With the trading day more than halfway over, the broad markets have pushed higher, seemingly recovering from Tuesday.

Other stocks mentioned: ANF, MAT, WDC, EBS, EOLS, GBIO, RDUS ...
1 month ago - 24/7 Wall Street

Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

REDWOOD CITY, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related disease...

4 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell...

5 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseas...

5 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell r...

5 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseas...

5 months ago - GlobeNewsWire

-- Subcutaneous formulation of lirentelimab was safe and well tolerated and demonstrated sustained eosinophil suppression support ing once monthly dosing -- -- Management to host conference call and web...

5 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related disease...

6 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell-related dise...

8 months ago - GlobeNewsWire

-- Phase 3 study in eosinophilic gastritis and/or eosinophilic duodenitis and Phase 2/3 study in eosinophilic esophagitis --  -- Top-line safety and efficacy results from both studies expected in the...

10 months ago - GlobeNewsWire

Allakos (ALLK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

Allakos Inc (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

11 months ago - Zacks Investment Research

REDWOOD CITY, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell-r...

11 months ago - GlobeNewsWire

-- Antolimab treatment provided durable symptom improvement and blood and tissue eosinophil depletion -- -- Symptomatic benefit increased with duration of antolimab treatment --

11 months ago - GlobeNewsWire

-- Antolimab (AK002) reduced gastrointestinal symptoms by 64 percent in patients with mast cell gastrointestinal disease -- -- Management to host conference call and webcast today at 5:00 pm ET --

1 year ago - GlobeNewsWire

-- Management to host conference call and webcast today at 5:00 pm ET -- REDWOOD CITY, Calif., March 24, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing antol...

1 year ago - GlobeNewsWire

Allakos Does It Again; bluebird And Sunesis Data: The Good, Bad And Ugly Of Biopharma

1 year ago - Seeking Alpha

Shares of Allakos Inc. rallied 37% in afternoon trading, to a record high.

1 year ago - Market Watch

REDWOOD CITY, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today anno...

1 year ago - GlobeNewsWire

Find out why these new healthcare stocks keep climbing, while most of their peers have underwhelmed.

Other stocks mentioned: GH, TWST
1 year ago - The Motley Fool

Investors were enthused about this biotech's positive phase 2 results for its lead investigational therapy, AK002.

1 year ago - The Motley Fool

Golden crosses and death crosses are common signals in technical analysis and refer to the relationship between short-term and long-term moving averages.

Other stocks mentioned: VRTX, BHVN, FOLD, JAZZ
1 year ago - 24/7 Wall Street

As of late, it has definitely been a great time to be an investor Allakos.

1 year ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for August 9th

Other stocks mentioned: BURBY, CSV, GAIA
1 year ago - Zacks Investment Research

About ALLK

Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headqu... [Read more...]

Industry
Biotechnology
IPO Date
Jul 19, 2018
CEO
Robert Alexander
Employees
125
Stock Exchange
NASDAQ
Ticker Symbol
ALLK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Allakos stock is "Buy." The 12-month stock price forecast is 135.88, which is an increase of 26.80% from the latest price.

Price Target
$135.88
(26.80% upside)
Analyst Consensus: Buy